ChromaDex (NASDAQ:CDXC) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of ChromaDex (NASDAQ:CDXC) in a report released on Friday. The firm issued a buy rating on the stock.

Several other equities analysts have also weighed in on CDXC. HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of ChromaDex in a report on Monday, March 17th. LADENBURG THALM/SH SH upped their price target on ChromaDex from $6.80 to $8.10 and gave the stock a “buy” rating in a research note on Wednesday, March 5th.

ChromaDex Price Performance

The company has a market capitalization of $611.50 million, a P/E ratio of 787.29 and a beta of 2.21. ChromaDex has a 52 week low of $2.31 and a 52 week high of $9.18. The business’s fifty day moving average price is $6.16 and its two-hundred day moving average price is $5.44.

Hedge Funds Weigh In On ChromaDex

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD boosted its position in shares of ChromaDex by 4.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 57,304 shares of the company’s stock valued at $304,000 after acquiring an additional 2,196 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in ChromaDex by 3.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 144,621 shares of the company’s stock valued at $767,000 after purchasing an additional 4,452 shares in the last quarter. USA Financial Formulas purchased a new position in ChromaDex in the 4th quarter worth approximately $25,000. BSW Wealth Partners grew its stake in ChromaDex by 5.6% in the 4th quarter. BSW Wealth Partners now owns 93,847 shares of the company’s stock worth $498,000 after buying an additional 5,000 shares in the last quarter. Finally, Teton Advisors Inc. increased its holdings in shares of ChromaDex by 25.0% in the 4th quarter. Teton Advisors Inc. now owns 25,000 shares of the company’s stock worth $133,000 after buying an additional 5,000 shares during the last quarter. 15.41% of the stock is currently owned by hedge funds and other institutional investors.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.